PDSバイオテクノロジーに関するコメント

$SPDR S&P Biotech ETF(XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...

$PDSバイオテクノロジー(PDSB.US)$ nice uptrend for a while here looks interesting!

$PDSバイオテクノロジー(PDSB.US)$ 👀

$PDSバイオテクノロジー(PDSB.US)$$PDSB $PDSB JUST ANNOUNCED 75% CANCER SURVIVAL RATE KABOOM STAMP 11/9/23 721AM

$PDSバイオテクノロジー(PDSB.US)$ Mayank Mamtani’s Buy rating for PDS Biotechnology Corporation is based on a number of significant factors. He highlighted the promising initial immunogenicity data from the ongoing VERSATILE-002 trial of PDS0101 + Keytruda for treating HPV16-positive head & neck squamous cell carcinoma. These findings were supportive of previously impressive results including 27% confirmed overall response rate, median progression-free survival of 8.1 months and an 80% one-year...

$PDSバイオテクノロジー(PDSB.US)$ PDS Biotech Announces Interim Safety and Immune Response Data From Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined With Docetaxel to Treat Metastatic Prostate Cancer

$PDSバイオテクノロジー(PDSB.US)$ PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated With PDS0101 in Combination With KEYTRUDA (Pembrolizumab)

$PDSバイオテクノロジー(PDSB.US)$ PDS Biotech Announces PDS0101 Combined With Chemoradiotherapy Associated With Rapid Decline in Circulating Tumor DNA (CtDNA/cfDNA)